ING Group’s Moleculin Biotech MBRX Stock Holding History

ING Group’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-9	Closed	-$122K	–	577
2016 Q3	$122K	Hold	9	–	–	﹤0.01%	561
2016 Q2	$132K	Buy	+9	New	+$146K	﹤0.01%	511

Other funds holding MBRX

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AWMS

Advocacy Wealth Management Services Atlanta, Georgia $2.26B AUM 13.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

WFG Advisors Dallas, Texas $442M AUM 12.46% 1-Year Est. Return

ING Group's MBRX Position: Q4 2016 in Review

ING Group sold out of Moleculin Biotech (MBRX) in Q4 2016, closing a stake of 9 shares — an estimated $122K sold.

ING Group first reported a position in MBRX in Q2 2016 and held it in 2 quarters. The position peaked at $132K in Q2 2016. 6 funds tracked by Wall St. Rank hold MBRX as of Q4 2016.

ING Group reported no remaining Moleculin Biotech position as of Q4 2016 after selling out during the quarter.
ING Group sold 9 Moleculin Biotech shares in Q4 2016, an estimated $122K.
ING Group first reported a position in Moleculin Biotech in Q2 2016 and held it in 2 quarters.
ING Group's Moleculin Biotech position peaked at $132K in Q2 2016.
6 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2016.

Based on ING Group's 13F filing for Q4 2016, filed 6 Feb 2017.